← Back to patent-cliff list
BG-136
Tier C — Watch / tradeBG-136
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Cell surface receptors
Indications (approved)：Colorectal cancer, Solid tumour, Melanoma
Regional status
US
-
EU
-
China
Phase II
2025-04-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BG-136?
Approved indications include: Colorectal cancer, Solid tumour, Melanoma.
When does the BG-136 patent expire?
No public expiry year is available for BG-136 yet; this page updates once verified.
How do I get a quote for BG-136 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30